S-1/A: Cardiff Lexington Corporation Files Amendment No. 5 to Form S-1/A, Eyes Nasdaq Uplisting

Cardiff Lexington Corporation files an amendment to its Form S-1/A registration statement, aiming to offer 1,600,000 shares of common stock and uplist to the Nasdaq Capital Market under the symbol CDIX.

Summary

• Cardiff Lexington Corporation filed Amendment No. 5 to its Form S-1/A registration statement with the SEC on June 12, 2024.
• The company intends to offer 1,600,000 shares of common stock to the public, with an estimated offering price between $4.00 and $6.00 per share.
• The company is pursuing an uplisting of its common stock to the Nasdaq Capital Market under the symbol CDIX, contingent upon the closing of the offering.
• The closing price of Cardiff Lexington's common stock on the OTC Pink Market was $7.00 on June 10, 2024.
• Executive officers and directors are expected to control approximately 72.54% of the company's total voting power after the offering.
• The company plans to use the net proceeds of approximately $6.7 million to repay $535,000 in debt and for working capital and general corporate purposes.
• The underwriters have a 45-day option to purchase up to 15% of additional shares to cover over-allotments.
• The company has agreed to issue warrants to the underwriters to purchase up to 5% of the shares sold in the offering at an exercise price equal to 125% of the public offering price.
• The company's healthcare business generated revenues of $11,853,266 in 2023 and $10,693,196 in 2022.
• The company reported a net income of $3,028,394 for 2023, compared to a net loss of $5,429,521 for 2022.
• For the three months ended March 31, 2024, the company had a net loss of $283,104.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is showing improved financial performance with a net income in 2023, but there are still risks and uncertainties associated with the business and the offering.

Positives

• The company achieved net income of $3.03 million in 2023, a significant turnaround from a $5.43 million net loss in 2022.
• The company's healthcare business is generating revenue.
• The company is attempting to uplist to the Nasdaq Capital Market.

Negatives

• The company had a net loss of $283,104 for the three months ended March 31, 2024.
• Executive officers and directors are expected to maintain significant voting control post-offering, around 72.54%.

Risks

• The company's uplisting to Nasdaq is contingent upon the closing of the offering.
• The market price of the company's common stock may be highly volatile.
• The company's officers and directors own a significant percentage of the company's outstanding voting securities which could reduce the ability of minority stockholders to effect certain corporate actions.
• The company's management has broad discretion as to the use of the net proceeds from the offering.
• The company has no current plans to pay cash dividends on its common stock for the foreseeable future.
• The company's shares of common stock may become subject to the penny stock rules, which would make it more difficult to trade the shares.
• The company is subject to ongoing public reporting requirements that are less rigorous than for larger, more established companies.

Future Outlook

The company expects to maximize organic growth by deploying increased working capital to expand utilization at current locations, open additional locations, and consider synergistic acquisitions in the healthcare sector.

Industry Context

The announcement reflects a company seeking to transition from the OTC Pink Market to the Nasdaq Capital Market, a move that typically aims to attract a broader investor base and enhance the company's visibility. The focus on the healthcare sector aligns with ongoing trends in the market, where demand for healthcare services continues to grow.

Comparison to Industry Standards

• It is difficult to compare Cardiff Lexington directly to industry standards without knowing the specific niche within healthcare they are operating.
• However, similar small-cap companies seeking Nasdaq uplisting often highlight growth strategies, financial improvements, and potential for future expansion to attract investors.
• The level of insider control (approximately 72.54% voting power) is higher than some comparable companies, which could be a concern for some investors but also signals strong management commitment.

Management Changes

Related Party Transactions

• A convertible promissory note in the principal amount of $5,000 was issued to Alex Cunningham, the Chief Executive Officer.
• In connection with the acquisition of Edge View on July 16, 2014, the company assumed amounts due to previous owners who are current managers of Edge View.
• The company has obtained short-term advances from Daniel Thompson, the Chairman of the Board.

Stakeholder Impact

• Shareholders: Potential dilution from the offering, but also potential for increased value if the company successfully executes its growth strategy.
• Employees: No immediate impact, but potential for long-term benefits if the company grows and becomes more successful.
• Customers: No immediate impact, but potential for improved services if the company invests in its healthcare facilities.
• Creditors: Debt repayment will improve the company's financial stability.

Next Steps

• The company needs to secure approval for listing on the Nasdaq Capital Market.
• The company needs to successfully execute the public offering.
• The company needs to effectively deploy the net proceeds from the offering.

Key Dates

Keywords

common stock, Nasdaq, offering, uplisting, healthcare, Cardiff Lexington, registration statement, securities